Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTER DAPT
NCT03023020Completed
- Sponsor
- ECRI
- Start
- Apr 2017
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands
- Countries
- 30
01
Overview
Randomised, open-label trial of aspirin in coronary artery disease (CAD) (2 arms), sponsored by ECRI. Primary endpoints: Net Adverse Clinical Endpoints at 11 months, Major Adverse Cardiac and Cerebral Events at 11 months and 1 more. Started Apr 2017; status: completed.
02
Drugs
aspirin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03023020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023020.